Alzchem Group Ag · XETR:ACT
Alzchem — Q1 2025 Earnings Presentation
31 slides from Alzchem's earnings presentation, Apr 30, 2025
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Presenters and date: April 30, 2025
1 2025 ANDREAS NIEDERMAIER, CEO DR. GEORG WEICHSELBAUMER, CSO ANDREAS LOSLER, CFO April 30, 2025
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q1 2025: Executive Summary
AGENDA — ANALYST PRESENTATION Q1 2025 Executive Summary
Slide 5: Highlights
2m Group AG / April 2025 HIGHLIGHTS Strong development continues in first quarter of 2025 Sales and EBITDA on expected level with growth in specialty chemicals segment Free Cashflow strongly impacted from first customer payments for Nitroguanidine capacity expansion Alzchem hosted global scientific
Slide 6: Agenda — II. Business and financial details
AGENDA — ANALYST PRESENTATION Q1 2025 ll. Business and financial details
Slide 7: Basics & Intermediates
NITRALZ® Berlka’ G CaD BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture. steel production and the automotive sector and as raw materials for the manufacture of
Slide 8: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Strong cost pressure from electricity prices in Q1 with expected sales SALES ANALYSIS 49.3 } 42.6 Volume - 9.5% Pp Qi Q2 Q3 Q4 Qt Q2 Q3 4 QI 2023 2023 2023 2023 2024 2024 2024 2024 2025 COMMENTS line in s p Metallurgy bt situation of th EBITDA imp: 0.1 01 Q2 93
Slide 9: Specialty Chemicals
a eo ( CREAMINO Drmex’ Bioselect®? DYHARD ##% Creapure‘ SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 10: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in Mé€) Segment drives significant revenue and profit growth SALES ANALYSIS Qi Q2 Q3 4 QI Q2 Q3 Q4 Ql 2023 2023 2023 2023 2024 2024 2024 2024 2025 h major . nd Creavita ith Dlumes 26.0 227 * Custom Manufacturing rn in demand from nan and Euro} n chemical industry with sm
Slide 11: Other & Holding
The "Other & Holding" segment offers infrastructure and energy supply services a at our locations for the chemicals segments and for external customers. a, . OTHER & HOLDING
Slide 12: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in me) Sustainable development with one offs in EBITDA Qi Q2 Q3 4 QI Q2 Q3 Q4 Ql 2023 2023 2023 2023 2024 2024 2024 2024 2025 a 0.5 03 Qi Q2 Q3 4 QI Q2 Q3 Q4 Ql 1-3 1-3 2023 2023 2023 2023 2024 2024 2024 2024 2025 2024 2025 1-3 2024 1-3 2025 COMMENTS
Slide 13: Financial Overview
FINANCIAL OVERVIEW Strong EBITDA and earnings growth SALES (in M€) Volume EBITDA (in M€) Price EBITDA margin (in %) Currency Earnings per Share (in €) cline in the fir EBITDA i with major im| cialty Improved EBITDA margin at a orted by positive Financial result str Walarels — mainly resulting from i
Slide 14: Balance Sheet & Cashflow Q1 2025
© Azchem Group AG BALANCE SHEET & CASHFLOW Q11 2025 Stable financial situation with positive net cash 21.12.20 483; litie ash oni qui Net financial debt (-) / asset (+) Cashflow Deviation Operati Im Free Cashflow 24,141 29,955 Balance sheet development mainly affected from stronger investing activit
Slide 15: KPI Impact of Nitroguanidine Expansion
em Group AG KPI IMPACT OF NITROGUANIDINE EXPANSION Timing and effects on balance sheet and P&L KPI EFFECTS KPI EFFECTS 2025/2026 2027 et seq. Cash / Assets + Cash / Assets = Other receivables ap Other receivables Vv Equity > Equity % Contract liabilities ap Contract liabilities Vv Equity ratio Sa Eq
Slide 16: Outlook 2025 (in M€)
OUTLOOK 2025 (in Me€) Alzchem on growth path in sales and EBITDA growth to approx. 580.0 ME FC 2025 COMMENTS * Outlook for 2025 confirmed * Major assumptions are still valid growth to approx No major im * Sales Growth FC 2025 .
Slide 17: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* “subject to change MAY 8& MAY 14 JUN 12 — 13 JUL 30 SEP 9 SEP 23 SEP 24 OCT 30 NOV 13 NOV 24 — 26 DEC 2 2025 2025 2025 2025 2025 2025 2025 2025 2025 2025 2025 ey Annual General Meeting 2025 German Spring Conference Berenberg Pan-European Discovery Conference Half-Y
Slide 18: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! QR-Code aera]
Slide 19: Investor Relations
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 20: Agenda — III. Back-Up
AGENDA — ANALYST PRESENTATION Q1 2025 lll. Back-Up
Slide 21: Balance Sheet
© Alzchem Group AG / April 2025 BALANCE SHEET Alzchem Group ALZCHIEM GROUP (IN TE) 3112.2024 31.03.2025 Deviation Intangible assets 367 3,807 736 37% Tangible assets 192,976 200,324 7,349 38% Investment properties Right of use (assets) 4023 3,540 -al] — -N9% Investments accounted for using the equit
Slide 22: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION costs costs PAYMENTS REMEASURE- PROVISION TAX ASSETS LIABILITY 31.12.2024 A MENTS 31.03.2025 31.03.2025 FINAN RESULT BALANCE SHEET P&L CASHFLOW, * Inter
Slide 23: Income Statement
INCOME STATEMENT Alzchem Group ALZCHEM GROUP (IN Te) a aoe as a woe as Deviation (Q1) Revenue 160,064 136191 128937 139,040 144.680 “5384 4% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 6,521 12,682 4310 -7,169 11,435 17,957 -275% Other income 3,558 3,731 3,716 6
Slide 24: Income Statement
INCOME STATEMENT Alzchem Group ALZCHEM GROUP (IN TE) sola soos Deviation (Q09) Revenue 150,064 144,680 “5384 -3.6% Increase (+) / Decrease (-) in inventorias of finished goods and work in progress “3521 11,436 17,957 -275.4% Other income 3,558 5,263 1705 47.9% Raw materials and consumables used ~53,
Slide 25: Cashflow Statement
© Alzchem Group AG / April 2025 CASHFLOW STATEMENT Alzchem Group 1-3 1-3 CASHFLOW (IN ME) 5024 oS Consolidated earnings before taxes 17,213 29,243 Depreciation on fixed and intangible assets 6534 6552 Decrease in pension provisions, ~633 758 Loss (+) / Profit ( } from the sale of non current assets
Slide 26: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER AX Alzchem Group v SALES caves oO o2 O8 C4 a Deviation Y (1) Te Te Te Te Te Te % Basics & Intermediates 44,21 44,538 -6,661 14% Specialty Chemicals 69,545 91,302 1,550 2% Other and Holding 7,007 6,955 274 Group Consolidation Alzchem Group, 150,432 126,599 120,824 142,794
Slide 27: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) SHANGHAI (CN) ATLANTA (USA) : . ~ } © SALES COMPANY © Alzchem Group AG / April 2025
Slide 28: Vertically integrated production of chemical products based on the NCN chain
© Alzchem Group AG / April 2025 Vertically integrated production of chemical products based on the NCN chain “VERBUND” — FULLY INTEGRATED BUSINESS MODEL us O O Segment Specialty Chemicals Segment Basics & Inter- mediates BENEFITS OF “VERBUND” * Full control of product quality and specifications * Lo
Slide 29: Our Products and Markets
OUR PRODUCTS AND MARKETS AN Successful with proven and new products in various industries (ay MAIN PRODUCTS DESCRIPTION END-MARKETS CREAMINO® = Anutritional additive for poultry and pigs Feed additive Creapure’ — Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutr
Slide 30: Our Products and Markets
© Alzchem Group AG / February 2024 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries n w = a < n ae a ta oo Wi [= e OTHER & HOLDING MAIN PRODUCTS DESCRIPTION END-MARKETS \N Calcium carbide-based mixtures for hot metal desulphurization Cad Steel industry Guanidine
Slide 31: Key Share Data
125, © Alzchem Group AG / March 20; KEY SHARE DATA Share details as of Apri SHARES OUTSTANDING. LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING DESIGNATED SPONSOR 28, 2025 10,176,335 EUR 101.8 EUR 1,036.0 m ACT A2YNT3 DEOOOA2YNT30 Frankfurt Stock Exchange — Prime Standard Baader Ban